We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
FSA
176
Franklin Street Advisors
North Carolina
$877K – – –
HWAM
177
Hennion & Walsh Asset Management
New Jersey
$867K +$16.8K +270 +2%
RIA
178
Regal Investment Advisors
Michigan
$850K +$236K +3,789 +39%
Qube Research & Technologies (QRT)
179
Qube Research & Technologies (QRT)
United Kingdom
$817K -$1.19M -19,165 -60%
Zurich Cantonal Bank
180
Zurich Cantonal Bank
Switzerland
$704K +$36K +577 +5%
PA
181
Profund Advisors
Maryland
$696K -$16.9K -271 -2%
Public Employees Retirement Association of Colorado
182
Public Employees Retirement Association of Colorado
Colorado
$656K – – –
ZIM
183
Zacks Investment Management
Illinois
$639K +$6.61K +106 +1%
Mariner
184
Mariner
Kansas
$638K +$96.8K +1,554 +18%
SWM
185
SeaCrest Wealth Management
New York
$614K +$605K +9,703 New
Arrowstreet Capital
186
Arrowstreet Capital
Massachusetts
$612K +$603K +9,671 New
RJFSA
187
Raymond James Financial Services Advisors
Florida
$558K +$173K +2,770 +46%
PCM
188
Prelude Capital Management
New York
$554K +$5.92K +95 +1%
QT
189
Quantbot Technologies
New York
$548K -$127K -2,038 -19%
CB
190
Commerce Bank
Missouri
$531K -$6.23K -100 -1%
FC
191
FORA Capital
Florida
$528K -$371K -5,960 -42%
LPL Financial
192
LPL Financial
California
$507K +$5.61K +90 +1%
AP
193
AtonRa Partners
Switzerland
$495K -$45.1K -724 -8%
Russell Investments Group
194
Russell Investments Group
United Kingdom
$491K +$244K +3,911 +102%
AIP
195
Ameritas Investment Partners
Nebraska
$490K +$34.6K +555 +8%
Mackenzie Financial
196
Mackenzie Financial
Ontario, Canada
$475K +$121K +1,946 +34%
LFAS
197
Level Four Advisory Services
Texas
$474K +$466K +7,483 New
CGH
198
Crossmark Global Holdings
Texas
$466K +$623 +10 +0.1%
CAM
199
Connacht Asset Management
New York
$460K -$32K -514 -7%
PNC Financial Services Group
200
PNC Financial Services Group
Pennsylvania
$452K +$57.9K +929 +15%
6 7
8
9 10

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.